ETRA Stock Forecast & Price Target

Electra Therapeutics is well positioned by a first-in-class SIRP-targeted platform that has already shown proof-of-concept in humans, with ipsoprubart producing a 100% eight-week overall survival rate and 100% overall response rate in 12 frontline mHLH patients, plus 7/8 tumor responses in lymphoma-associated cases. Its lead program addresses a severe, underserved orphan market with no approved broad therapy, a U.S. diagnosed incidence of ~12,600 in 2025 that could reach nearly 17,500 in 2028, and it has Breakthrough Therapy and PRIME designations that strengthen regulatory momentum. The balance of a registrational sHLH program, additional oncology shots on goal, and ELA822’s selective T-cell depletion data in preclinical models supports meaningful upside while the company’s cash and IPO proceeds are expected to fund operations into 2029.

Electra Therapeutics is burdened by a lack of revenue visibility, with no product sales expected in 2026 or 2027 and no approved products to offset rising development costs. Heavy R&D and G&A spending, projected at $86.5 million and $22 million in 2026 and $120 million and $40 million in 2027, is expected to drive operating losses of $108.5 million and $160 million, while free cash outflows of about $105.4 million and $154.8 million underscore persistent cash burn. Its lead asset, ipsoprubart, still faces substantial clinical, regulatory, reimbursement, and execution risk, and ELA822 remains early stage, leaving the company dependent on uncertain financing and commercialization beyond 2030.